On August 21, KEYMED BIO-B rose 5.14% in regular trading, trading at HK$81.8/share, with turnover of HK$67.91 million, extending gains from the prior session.

The rally follows multiple catalysts announced on August 19. The company's board approved a preliminary plan to issue RMB-denominated shares for listing on the Shanghai Stock Exchange STAR Market, though no application has yet been submitted to regulators. Simultaneously, the company reported H1 results showing revenue of RMB 6.17 billion, up 24% year-over-year, and net profit of RMB 12.18 billion, a historic turnaround from a loss of approximately RMB 79 million in the prior-year period.

The profit turnaround was primarily driven by a RMB 16.8 billion pre-tax gain from the disposal of its Ouro Medicines equity stake. Core product Kangyueda generated product revenue of RMB 3.93 billion, surging 132% year-over-year, supported by national medical insurance inclusion and an expanded commercial team covering over 1,600 hospitals across 260 cities.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)